TABLE 2.
Prevalence of RBD and NC antibodies for SurveyFall21 and SurveySpring22 a
| Vaccination | COVID-19 | |||
|---|---|---|---|---|
| Vax+ | Vax− | SR+ | SR− | |
| Serosurvey September 2021 (N = 1,060) | ||||
| n = 978 (92.3%) | n = 82 (7.7%) | n = 204 (19.2%) | n = 856 (80.8%) | |
| RBD | ||||
| Beckman | 904 (92.4%) | 31 (37.8%) | 189 (92.6%) | 746 (87.1%) |
| MISPA | 967 (98.9%) | 54 (65.9%) | 204 (100.0%) | 817 (95.4%) |
| NC | ||||
| Bio-Rad | 176 (18.0%) | 33 (40.2%) | 116 (56.9%) | 93 (10.9%) |
| MISPA | 307 (31.4%) | 49 (59.8%) | 172 (84.3%) | 184 (21.5%) |
| Serosurvey March 2022 (N = 1,379) | ||||
| n = 1,318 (95.6%) | n = 61 (4.4%) | n = 528 (38.3%) | n = 851 (61.7%) | |
| RBD | ||||
| Beckman | 1,290 (97.9%) | 39 (63.9%) | 516 (97.7%) | 813 (95.5%) |
| MISPA | 1,302 (98.8%) | 49 (80.3%) | 517 (97.9%) | 834 (98.0%) |
| NC | ||||
| Bio-Rad | 500 (37.9%) | 37 (60.7%) | 380 (72.0%) | 157 (18.4%) |
| MISPA | 662 (50.2%) | 45 (73.8%) | 462 (87.5%) | 245 (28.8%) |
a
Not included in this analysis were four samples that did not have vaccination or COVID-19 information. Vax+ and Vax− indicates vaccinated and not-vaccinated; SR+ and SR− indicates self-reported COVID-19 positive and negative.